Brief: UK's NICE Says Benefits Of Alzheimer’S Treatment Lecanemab Too Small To Justify Cost To NHS
22/08/2024 10:00
Aug 22 (Reuters) - UK'S NICE:
* UK'S NICE: BENEFITS OF ALZHEIMER’S TREATMENT LECANEMAB ARE
TOO
SMALL TO JUSTIFY COST TO THE NHS
* UK'S NICE: ISSUED DRAFT GUIDANCE FOR CONSULTATION NOT
RECOMMENDING LECANEMAB FOR USE ON NHS AS IT IS NOT COST
EFFECTIVE USE OF LIMITED NHS FUNDING
Source text for Eikon: ID:
Further company coverage: 4523.T
((Reuters.Briefs@thomsonreuters.com;))
Recent news on BioArctic AB (publ)
See all newsBrief: BioArctic Gets Leqembi Pen Subcutaneous Formulation Approval In Japan
Brief: BioArctic Says Leqembi Subcutaneous Formulation Approved For Initiation Treatment In China
Brief: BioArctic Says Canada's Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement Of Leqembi
Sweden's BioArctic Q2 revenue falls despite higher Leqembi royalties
Brief: BioArctic Q2 Net Sales Down At SEK 247.5 Mln